Rhabdomyosarcoma

SX Skapek, A Ferrari, AA Gupta, PJ Lupo… - Nature reviews disease …, 2019 - nature.com
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and
represents a high-grade neoplasm of skeletal myoblast-like cells. Decades of clinical and …

Current and future treatment strategies for rhabdomyosarcoma

C Chen, H Dorado Garcia, M Scheer… - Frontiers in …, 2019 - frontiersin.org
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, and can be
subcategorized histologically and/or based on PAX-FOXO1 fusion gene status. Over the last …

Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium

JF Shern, J Selfe, E Izquierdo, R Patidar… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood.
Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent …

Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma

M Hegde, SK Joseph, F Pashankar, C DeRenzo… - Nature …, 2020 - nature.com
Refractory metastatic rhabdomyosarcoma is largely incurable. Here we analyze the
response of a child with refractory bone marrow metastatic rhabdomyosarcoma to …

Integrative clinical sequencing in the management of refractory or relapsed cancer in youth

RJ Mody, YM Wu, RJ Lonigro, X Cao, S Roychowdhury… - Jama, 2015 - jamanetwork.com
Importance Cancer is caused by a diverse array of somatic and germline genomic
aberrations. Advances in genomic sequencing technologies have improved the ability to …

[HTML][HTML] Next-generation personalised medicine for high-risk paediatric cancer patients–The INFORM pilot study

BC Worst, CM van Tilburg, GP Balasubramanian… - European journal of …, 2016 - Elsevier
Abstract The 'Individualized Therapy for Relapsed Malignancies in Childhood'(INFORM)
precision medicine study is a nationwide German program for children with high-risk …

Outcomes for children and adolescents with cancer: challenges for the twenty-first century

MA Smith, NL Seibel, SF Altekruse, LAG Ries… - Journal of clinical …, 2010 - ascopubs.org
Purpose This report provides an overview of current childhood cancer statistics to facilitate
analysis of the impact of past research discoveries on outcome and provide essential …

The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets

CM Van Tilburg, E Pfaff, KW Pajtler, KPS Langenberg… - Cancer discovery, 2021 - AACR
INFORM is a prospective, multinational registry gathering clinical and molecular data of
relapsed, progressive, or high-risk pediatric patients with cancer. This report describes long …

Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft‐Tissue Sarcoma Committee experience and rationale for current COG studies

S Malempati, DS Hawkins - Pediatric blood & cancer, 2012 - Wiley Online Library
The prognosis for children and adolescents with rhabdomyosarcoma (RMS) has improved
with refinements in multi‐modal therapy. Since 1972, the Intergroup Rhabdomyosarcoma …

Rhabdomyosarcoma

R Dasgupta, J Fuchs, D Rodeberg - Seminars in pediatric surgery, 2016 - Elsevier
A malignant tumor of striated muscle origin, rhabdomyosarcoma (RMS) is a childhood tumor
that has benefited from nearly 30 years of multimodality therapy, culminating in a> 70 …